Web Results

www.linkedin.com/in/simon-pedder-632240b

View Simon Pedder's profile on LinkedIn, the world's largest professional community. Simon has 4 jobs listed on their profile. See the complete profile on LinkedIn and discover Simon's connections and jobs at similar companies.

www.prnewswire.com/news-releases/athenex-announces-the-addition-of-simon-pedder-phd-and-raymond-yeung-msc-mba-to-its-global-leadership-team-300217379.html

Feb 9, 2016 ... BUFFALO, N.Y. and HONG KONG, Feb. 9, 2016 /PRNewswire/ -- Athenex, Inc. announced today that Simon Pedder, PhD, has joined Athenex as Vice President of Corporate Strategy and Business Development based in the U.S. and Mr. Raymond Yeung, MSc, MBA has joined as Senior Director and ...

www.crunchbase.com/person/simon-pedder-2

Dr. Simon Pedder, Ph.D., served as the Founder and Chief Executive Officer of Chelsea Therapeutics International Ltd. from April 2004 until July 2012. Previously Dr. Pedder served as an Executive Officer and Vice President of Pharmaceutical Business, Oncology at Hoffmann-La Roche Inc. Prior to that he was Vice ...

globenewswire.com/news-release/2017/11/20/1197421/0/en/Delcath-Enhances-Board-of-Directors-With-Appointment-of-Industry-Veteran-Dr-Simon-Pedder.html

Nov 20, 2017 ... NEW YORK, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. ( OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that Simon Pedder, Ph.D., a scientist and pharmaceutical executive with a greater than 30-year ...

www.athenex.com/our-team/our-leadership-team

Simon Pedder, PhD. Chief Business and Strategy Officer, Proprietary Products. Simon has a long career in drug development including recent leadership roles as President and CEO of Cellectar Biosciences, President and CEO of Chelsea Therapeutics, Vice President of Oncology Pharma Business at Hoffmann- LaRoche, ...

investor.cellectar.com/releasedetail.cfm?releaseid=837130

Apr 2, 2014 ... MADISON, Wis., April 2, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (OTCQX:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that effective April 1, 2014, Dr. Simon Pedder transitioned to President and ...

www.xconomy.com/wisconsin/2015/06/16/cellectar-biosciences-appoints-new-ceo-amid-recent-turmoil

Jun 16, 2015 ... Cellectar Biosciences today appointed a new president and CEO, the latest in a series of unexpected moves in recent weeks by the Madison, WI-based biotech company. Seasoned drug and device industry executive Jim Caruso is taking over for Simon Pedder, who resigned his positions as Cellectar CEO ...

www.charlotteobserver.com/living/health-family/article9099398.html

Feb 24, 2014 ... Oliveto said Chelsea benefits because it doesn't have to pay certain FDA fees required for non-orphan drugs, didn't have to enroll as many patients in the early clinical trials, and will get “market exclusivity” to sell Northera for seven years . Chelsea was founded in 2004 by Simon Pedder, who resigned as ...

www.federmanlaw.com/Websites/federmanlaw/images/NotSettChelsea.pdf

Jun 21, 2016 ... is with Defendants Chelsea, Simon Pedder, and William D. Schwieterman (“ Defendants”). • The Settlement Provides that Chelsea will cause $5,500,000 to be paid to the Class. After payment of attorneys' fees, costs, and expenses, the Settlement proceeds will be distributed to investors who are members of ...